Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 34.3% year on year to $181.9 million. On the other hand, the company’s full-year revenue guidance of $925 million at the midpoint came in 8.2% above analysts’ estimates. Its GAAP profit of $0.26 per share was 39% below analysts’ consensus estimates.
Marqeta’s (NASDAQ:MQ) Q4 Sales Beat Estimates, Stock Jumps 12.2%
Leading edge card issuer Marqeta (NASDAQ: MQ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 14.3% year on year to $135.8 million. Guidance for next quarter’s revenue was better than expected at $135.7 million at the midpoint, 1.7% above analysts’ estimates. Its GAAP loss of $0.05 per share was in line with analysts’ consensus estimates.
Energy Recovery’s (NASDAQ:ERII) Q4 Earnings Results: Revenue In Line With Expectations
Energy recovery device manufacturer Energy Recovery (NASDAQ:ERII) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 17.3% year on year to $67.08 million. Its non-GAAP profit of $0.50 per share was 24% above analysts’ consensus estimates.
Red Robin (NASDAQ:RRGB) Reports Q4 In Line With Expectations, Stock Jumps 11.4%
Burger restaurant chain Red Robin (NASDAQ:RRGB) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 7.7% year on year to $285.2 million. On the other hand, the company’s full-year revenue guidance of $1.24 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP loss of $0.94 per share was 63.8% below analysts’ consensus estimates.
Sarepta Therapeutics’s (NASDAQ:SRPT) Q4: Beats On Revenue
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced better-than-expected revenue in Q4 CY2024, with sales up 65.9% year on year to $658.4 million. Its non-GAAP profit of $1.90 per share was 7.8% below analysts’ consensus estimates.
eBay (NASDAQ:EBAY) Posts Q4 Sales In Line With Estimates But Stock Drops
Online marketplace eBay (NASDAQ:EBAY) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $2.58 billion. On the other hand, next quarter’s revenue guidance of $2.54 billion was less impressive, coming in 2.3% below analysts’ estimates. Its non-GAAP profit of $1.25 per share was 4.3% above analysts’ consensus estimates.
Nvidia’s (NASDAQ:NVDA) Q4 Sales Top Estimates, Provides Encouraging Quarterly Revenue Guidance
Leading designer of graphics chips Nvidia (NASDAQ:NVDA) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 77.9% year on year to $39.33 billion. Guidance for next quarter’s revenue was optimistic at $43 billion at the midpoint, 2.1% above analysts’ estimates. Its non-GAAP profit of $0.89 per share was 5.2% above analysts’ consensus estimates.
Teladoc’s (NYSE:TDOC) Q4 Earnings Results: Revenue In Line With Expectations But Stock Drops 11.7%
Digital medical services platform Teladoc Health (NYSE:TDOC) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 3% year on year to $640.5 million. On the other hand, next quarter’s revenue guidance of $618.5 million was less impressive, coming in 2.4% below analysts’ estimates. Its GAAP loss of $0.28 per share was 26.1% below analysts’ consensus estimates.
FTAI Aviation (NASDAQ:FTAI) Beats Q4 Sales Targets
Aircraft leasing company FTAI Aviation (NASDAQ:FTAI) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 59.5% year on year to $498.8 million. Its GAAP profit of $0.84 per share was 6.1% below analysts’ consensus estimates.
Sweetgreen (NYSE:SG) Posts Q4 Sales In Line With Estimates But Stock Drops 16.1%
Casual salad chain Sweetgreen (NYSE:SG) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 5.1% year on year to $160.9 million. On the other hand, next quarter’s revenue guidance of $164.5 million was less impressive, coming in 7.7% below analysts’ estimates. Its GAAP loss of $0.25 per share was 16.4% below analysts’ consensus estimates.